Review
Published · Updated · 1 min read
Dimetindene: routine risk minimisation in the plan for Fazex gel
What it means for practice
The plan provides for routine risk minimisation and adverse reaction monitoring. The absence of listed risks in the summary should not be interpreted as evidence that adverse reactions do not occur.
Summary
The supplied abstract describes the risk management plan for Fazex gel, which contains dimetindene. It discusses use for skin itching, sunburn, minor burns and allergic skin irritation. This is a description of risk management measures, not a report of clinical trial results.
What the plan includes
The abstract lists routine risk minimisation measures, including packaging information and prescription status. The specific prescription status is not provided in the supplied description. The plan also includes adverse reaction monitoring and emphasises consistency between safety information and existing data.
How to interpret the safety information
According to the abstract, no identified or potential risks or missing safety information are currently noted. Additional post-authorisation studies are not required. These statements describe the content of the plan but do not provide a quantitative estimate of adverse reaction frequency.
The practical emphasis is on routine risk minimisation measures and continued adverse reaction monitoring. Link to the document.
Source
-
Фазекс, гель, ТОВ “КУСУМ”, Україна.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
